Kornimate/medical-research-clean huggingface dataset:
bilateral sacroiliac joint (sij) injection in lumbar disc prolapse

Conditions: Lumbar Disc Herniation; Sciatica; Low Back Pain, Mechanical; Spine Stiffness

Summary: bilateral sacroiliac joint injection in symptomatic lumbar disc prolapse under ultrasound guidance and studying the effect of this technique on pain, spine mobility and activity of daily living.

86 patients with lumbar disc prolapse diagnosed by either mri or ct will be included. all of them aged \> 18 years with no special condition for the duration of disc prolapse. all of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. all participants had no or poor response to conservative treatment. previous surgery, severe facet arthropathy, ankylosing spondylitis, sensory or motor deficit and wedge fracture were considered as exclusion criteria. distraction, compression, thigh thrust, and sacral thrust were used to assess sij dysfunction only at baseline before injection. fingertip to floor and oswestry disability index (odi) were used to assess mobility and function of the spine at baseline (before and after injection) and after 2 and 16 weeks. visual analogue scale (vas) was used for pain appraisal at the same intervals. participants will be randomly assigned into active and control group using 1:1 allocation. in the active group bilateral sij injection will be performed under ultrasound us guidance. under us guidance a 22g spinal needle, where 1 ml 2 % lidocaine hydrochloride (xylocaine, astrazeneca) mixed with triamcinolone 40 milligrams (kenacort, bristol myers squip) will be injected in each sij.

Eligibility criteria:
inclusion criteria: * lumbar disc prolapse diagnosed by either mri or ct were included. * all of them aged \> 18 years * no special condition for the duration of disc prolapse. * all of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. * all participants had no or poor response to conservative treatment exclusion criteria: * previous surgery * severe facet arthropathy * ankylosing spondylitis * sensory or motor deficit * wedge fracture

Keywords: disc prolapse sacroiliac joint injection ultrasound
role of biomarkers in disease progression in samples from patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. purpose: this research trial studies the role of biomarkers in disease progression in samples from patients with acute myeloid leukemia.

objectives: * to determine the subcellular localization of the mll-af1q fusion protein in leukemia cells. outline: cryopreserved specimens are analyzed for mll-af1q fusion protein and af1 gene expression by mass spectrometry, western blot analysis, semi-quantitative pcr, and qpcr.

Eligibility criteria:
disease characteristics: * cryopreserved acute myeloid leukemia specimens patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: adult acute myeloid leukemia childhood acute myeloid leukemia/other myeloid malignancies
antibiotic prophylaxis in ragged placental membranes

Conditions: Endometritis Postpartum; Endometritis; Membranes; Retained

Summary: in some centres, women are routinely given a course of antibiotics postnatally if ragged placental membranes were present at delivery. the investigators examined the necessity such an intervention.

postpartum endometritis resulting in sepsis remain one of the leading cause of maternal mortality in developing countries. ragged placental membrane is a risk factor for endometritis and is not infrequently encountered. several hospitals in malaysia, largely those geographically-removed currently practice administering prophylactic antibiotics for women with ragged placental membranes. the aim is to reduce the risk of postpartum endometritis in a subgroup of women who may present in dire straits. the investigators sought to examine the necessity of such protocols.

Eligibility criteria:
inclusion criteria: all women who delivered vaginally beyond 24+0 weeks of gestation and were found to have ragged or retained placental membranes immediately after the third stage of labour were invited to participate in the study. exclusion criteria: 1. fever, within 5 days preceding delivery (axillary temperature \> 37.5oc on 2 or more occasions at least 1 hour apart or temperature \> 38oc on one occasion). this also includes intrapartum fever. 2. required oral or intravenous antibiotics for any other obstetric-related (ex. third or fourth degree tears, preterm prelabour rupture of membranes) or non- obstetric related (ex. pneumonia, acute pyelonephritis) reasons 3. prolonged rupture of membrane (\>18 hours) 4. retroviral disease, on long term oral or parenteral steroid or receiving other forms of immunosuppressants, including chemotherapy within the last one year. 5. vaginal delivery for an intrauterine death 6. penicillin allergy

Keywords: antibiotic endometritis placental membranes prophylaxis ragged membranes
macrophages effect on chemoresistance

Conditions: the Focus of the Study is Macrophage-induced Chemoresistance in Pancreatic Carcinoma Cells During Chemotherapy.

Summary: macrophages are derived from monocytes recruited to the tumor site and stimulated by specific chemokines secreted by tumor cells. these tumor associated macrophages (tams) have been postulated as being involved in the progression of cancer. based on our preliminary findings and on published data we hypothesized that macrophage-induced chemoresistance (mic) can promote survival of pancreatic carcinoma cells during chemotherapy. the overall goal of this study is to evaluate the mechanism of mic in an in-vitro model of pancreatic ductal adenocarcinoma (pda). methods: 1. the human pda cell line panc1 will be grown in suitable conditions. 2. macrophages will be produced by incubating mononuclear cells from the blood of healthy donors in medium with m-csf for 7 days. 3. tams will be generated by culturing these macrophages with tumor-culture conditioning medium (tccm) of pda cells for an additional 72 hours. 4. human pancreatic cells (panc1) will be treated with gemcitabine following exposure to macrophages cm. 5. cell proliferation will be quantified by light microscopy and by an xtt cell proliferation assay kit.


Eligibility criteria:
inclusion criteria: * healthy people exclusion criteria: * refusal to participate

Keywords: macrophages adenocarcinoma chemoresistance
determine if the stress that comes with not developing an erection affects tadalafil effects

Conditions: Impotence

Summary: to determine if patients who are distressed over having problems getting or maintaining an erection react differently to the medication than those who are not stressed over the issue.


Eligibility criteria:
inclusion criteria: * 3 months history of erectile dysfunction (ed) * anticipate a monogamous relationship with a female sexual partner * be able to make minimum required sexual intercourse attempts * abstain from using any other ed treatment exclusion criteria: * nitrate use * participated in previous tadalafil study or have a current tadalafil prescription * heart attack within the last 90 days * kidney problems * certain heart problems
evaluation of the exercise for wellbeing pathway at york st john university

Conditions: Mental Health

Summary: in autumn 2024, york st john university launched a physical activity programme for university students facing mental health challenges. the purpose of this project is to conduct a mixed-methods evaluative study of this new service over a 6-month period. it is anticipated that 20-40 students will be recruited to the study, which will assess the following: assess the following: feasibility, the extent to which the service can be delivered successfully; acceptability, the extent to which the service is considered appropriate, satisfactory, or attractive by programme recipients and intervention delivery staff; fidelity, the extent to which the key service components (e.g., assessment procedures, physical activity programme) were implemented as planned and adaptations were made; preliminary effects, with relation to physical, mental and social health outcomes.


Eligibility criteria:
inclusion criteria: * student enrolled at york st john university * age 18 years and over * undertaking a course which requires attendance at york st john university's lord mayor's walk campus * presenting to the student wellbeing team with mild-to-moderate mental health concerns (defined as experiencing symptoms of poor mental health such as feeling depressed or socially isolated, prolonged stress and anxiety, or experiencing academic decline that makes their daily life more difficult but maintain daily functioning) and expressing an interest in enhancing their mental health and daily functioning exclusion criteria: * unwilling or unable to provide written informed consent * unable to attend (or to participate in) the scheduled physical activity sessions * unsuccessful physical activity clearance using the physical activity readiness questionnaire (par-q+)

Keywords: exercise physical activity anxiety psychological distress depression university student
the involvement of eukaryotic translation initiation factor 4e (eif4e) in human placental implantation and in the pathological pregnancies: preeclampsia and iugr

Conditions: Pregnancy; Preeclampsia

Summary: the involvement of eukaryotic translation initiation factor 4e (eif4e) in human placental implantation and in the pathological pregnancies: preeclampsia and iugr.

4 groups

Eligibility criteria:
inclusion criteria: * post top or delivery exclusion criteria: -

Keywords: iugr pet eif4e translation initiation factor 4e (eif4e) in human placental implantation and in the pathological pregnancies: preeclampsia and iugr
angiotensin-ii receptor antibodies blockade with losartan in patients with lupus nephritis

Conditions: Atherosclerosis; Lupus Nephritis

Summary: antibodies directed against angiotensin-ii receptor (at1-ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. they act by binding to the at1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (arb). in this randomized open clinical trial the investigators will study the effect of the blockade of at1-ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.

angiotensin-ii type 1 receptor antibodies (at1r-ab) are agonist antibodies directed against the second loop of the at1 receptor. these antibodies have been studied in human diseases such as preeclampsia, transplantation and scleroderma. a previous study from the investigators' group found an elevated prevalence of at1r-ab in patients with lupus nephritis. as these antibodies have been linked to atherosclerosis development this open randomized clinical trial was designed to evaluate the effect of at1r-ab blockade with losartan compared to the use of enalapril in the progression of carotid intima-media thickness (cimt) in patients with active lupus nephritis. biopsy-proven lupus nephritis patients who tested positive for at1r-ab will be performed a cimt measurement by doppler ultrasound at the time of the biopsy and then at 12-months follow up. the primary outcome will be the change in the cimt in the course of 12 months in both groups.

Eligibility criteria:
inclusion criteria: * signed consent form for the study * biopsy-proven lupus nephritis with proteinuria \> 1.5g/g by 24 hour urine protein to creatinine ratio * need for immunosuppressive induction to remission therapy according to the treatment physician * systemic lupus erythematosus diagnosis based on at least 4 american college of rheumatology criteria * age between 16 and 50 years exclusion criteria: * patient does not want to participate in the study * comorbid disease such as diabetes mellitus with macro/microangiopathy, previous diagnosis of hypertension \>5 years, scleroderma * comorbid findings in the histopathological analysis of the renal biopsy
a trial of hhpg-19k injection and auto-hhpg-19k injection in prevention of chemotherapy-related moderate to severe neutropenia of patients with nonmyeloid malignancies

Conditions: Patients With Nonmyeloid Malignancies Receiving Antineoplastic Therapy Based on Chemotherapy Regimens at Moderate to High Febrile Neutropenia (FN) Risk

Summary: the study is being conducted to evaluate the preference, and safety of hhpg-19k injection and auto-hhpg-19k injection in prevention of chemotherapy-related moderate to severe neutropenia of patients with nonmyeloid malignancies.


Eligibility criteria:
inclusion criteria: 1. the patient signs the informed consent form and voluntarily participate in this study; 2. age ≥18 years; 3. have the ability to read and understand chinese; 4. pathologically or histologically confirmed diagnosis of non-myeloid malignant tumor diseases (including solid tumors and malignant hematologic tumors); 5. patients who plan to receive at least two consecutive cycles of anti-tumor trerapy based on a moderate to high fn risk chemotherapy regimen (see appendix 4 for details of the chemotherapy regimen); 6. the investigator determines that the patient are eligible to receive administration of hhpg-19k injection and auto-hhpg-19k injection (delivered through an adhesive patch automatic drug delivery device); 7. ecog (eastern cooperative oncology group score) score 0-1 points; 8. expected survival ≥3 months; 9. good function of major organs, meeting the following criteria: 1. neutrophil count ≥1.5 ×109/l; 2. platelet count≥75 ×109/l; 3. hemoglobin level≥80 g/l. 10. women of childbearing age must take a blood pregnancy test within 3 days before randomization, and the result is negative, and they should not be lactating. female subjects of childbearing age and male subjects whose partners are women of childbearing age must agree to approach highly effective contraceptive methods from the day of signing the informed consent form until at least 6 months after the last administration (for female subjects) or 3 months after the last administration (for male subjects). exclusion criteria: 1. women who are planning to become pregnant or breastfeeding; 2. allergic to polyacrylate adhesives, hhpg-19k, polyethylene glycol recombinant human granulocyte stimulating factor, recombinant human granulocyte stimulating factor and other preparations expressed in escherichia coli; 3. having a history of bone marrow transplantation and/or stem cell transplantation; 4. other situations deemed unsuitable for inclusion in the study as determined by the investigator
a study assessing the safety and efficacy of de-117 in subjects with poag or oh who are non-/low-responders to latanoprost: fuji study

Conditions: Primary Open Angle Glaucoma or Ocular Hypertension

Summary: the purposes of this study are to investigate the effect of intraocular pressure lowering efficacy and safety of de-117 ophthalmic solution in subjects with primary open-angle glaucoma or ocular hypertension who are non-/low-responders to latanoprost ophthalmic solution.


Eligibility criteria:
inclusion criteria: * primary open angle glaucoma or ocular hypertension exclusion criteria: * patients at risk of progression of visual field loss * patients with severe visual field defect * patients with any diseases that preclude participation in this study for safety reasons
impact of oncodoc2 on guideline compliance in the management of breast cancer

Conditions: Breast Cancer

Summary: the objective of the study is to evaluate how the use of oncodoc2, a computerized guideline-based decision support system, could improve the compliance of multidisciplinary staff meeting decisions with local clinical practice guidelines in the management of non-metastatic breast cancer.

in france, to promote the quality of cancer care, decisions have currently to be made according to clinical practice guidelines (cpgs) during regularly organized multidisciplinary staff meetings (msms). dissemination of textual cpgs has a poor impact on clinical practice as opposed to the use of clinical decision support systems (cdsss) known to improve compliance with cpgs. oncodoc2 is a cdss providing patient-specific recommendations based on cpgs for non-metastatic female breast cancer management elaborated by the cancerest intermedical collaboration.the main goal of the study is to evaluate the effect of the routine use of oncodoc2 during msms on compliance of msm decisions with local cpgs. impact will be measured by the compliance rate of msm decisions with oncodoc2 recommendations. the design of the study relies on a cluster randomized controlled trial. under the assumption of a baseline compliance rate of 70% without intervention, an expected compliance rate of 90% in the intervention group (α = 5%, β = 20%), an inter-cluster variability of 5%, and 59 decisions per center, the required number of centers is 3 in each group, or 177 decisions in each arm. the study will be conducted in cancer care centers (public and private) from paris area, france.this prospective trial will be conducted in two steps. first, baseline compliance rates will be measured in each center. then, the 6 centers will be randomized into 2 arms. in the intervention arm, oncodoc2 will be used during msms at decision time. every case of non-adherence with system recommendations will have to be justified by clinicians. in both arms and after each msm, msm decisions will be recorded as well as patient characteristics and oncodoc2 will be used for each patient case to get system recommendations. in the intervention arm, oncodoc2 recommendations obtained by msm will also be recorded, as well as the reason for non following recommendations in case msm decision does not comply with guidelines.

Eligibility criteria:
inclusion criteria: * non metastatic, including invasive and in situ, breast cancers as well as axillary cancer without breast tumor. * at least one therapeutic msm decision. exclusion criteria: * breast disease without cancer * metastatic breast cancer * male breast cancer * breast cancer cases when medical records are not accessible to investigators * management but not therapeutic breast cancer decisions (diagnostic investigations, treatment follow-up, delayed decisions...)

Keywords: clinical practice guidelines guideline adherence clinical decision support systems randomized controlled trial intervention study
double blind, placebo-controlled, study of the safety, tolerability and pharmacokinetics of ain457 in rheumatoid arthritis patients

Conditions: Rheumatoid Arthritis

Summary: evaluate the safety, tolerability and pharmacokinetics of ain457 when administered as a single dose (intravenous infusion) in patients with active rheumatoid arthritis in combination with a stable dose of methotrexate. and to compare efficacy on the dose groups.


Eligibility criteria:
inclusion criteria: * male and female patients with active rheumatoid arthritis in combination with a stable dose of methotrexate aged 18-75 years may participate in this trial. * post menopausal or surgically sterile female patients are allowed. women of child-bearing potential may participate if they are on a stable dose of methotrexate and if they are practicing effective contraception for at least 6 months prior to screening, willing to use 2 forms of contraception, including at least 1 barrier method during the study and for at least 2 months following the completion/discontinuation of the study. * patients must have a diagnosis of active rheumatoid arthritis of stages i, ii or iii (acr 1987 revised classification for criteria for ra). disease duration of at least 6 months prior to randomization is essential; exclusion criteria: * current treatment with anti-tnf-α or anti il-1 therapy (or other biological therapy). * patients with congestive heart failure or poorly controlled diabetes mellitus (hba1c value ≥10%). * presence of any major chronic inflammatory autoimmune diseases like psoriasis, psoriatic arthritis, spondyloarthropathy, inflammatory bowel disease or sle that can mimic rheumatoid arthritis diagnosis or that can interfere with efficacy evaluation in the study. * history of renal trauma, glomerulonephritis or patient with one kidney. * pregnant or breastfeeding women will be excluded. * a positive tuberculin skin test. other protocol-defined inclusion/exclusion criteria may apply.

Keywords: rheumatoid arthritis
the effects of video games in stroke

Conditions: Stroke; Hemiplegia

Summary: aims: to establish whether the effectiveness of conventional treatment is increased when it is complemented with video-based therapy, whether specific rehabilitation or commercial after subacute stroke. design: randomized clinical trial with pre / post-test and follow-up evaluation, assessor blinded study. methodology: three different groups: conventional treatment, conventional treatment and commercial videogame, or conventional treatment and specific rehabilitation videogame. the three groups completed 12 sessions.


Eligibility criteria:
inclusion criteria: * patients with stroke * hemiplegia on the non-dominant side * more than 1 month since the stroke * score 3 in the shoulder and 2 in the elbow in the modified medical research council scale * no auditory alterations * no visual disturbances * mini mental scale greater than or equal to 24 exclusion criteria: * patients with unstable blood pressure or angina. * history of seizures. * do not use video games
prevention of disease progress in chronic hepatitis c patients with liver fibrosis (study p02570am2)(completed)

Conditions: Chronic Hepatitis C; Liver Fibrosis

Summary: the objective of the study is to evaluate the safety and efficacy of peg-intron versus no treatment for the prevention of fibrosis progression in adult participants with moderate to severe liver fibrosis secondary to chronic hepatitis c, who failed peg-intron plus rebetol treatment in protocol p02370 (nct00039871).


Eligibility criteria:
inclusion criteria: * age at entry in study p02370 (nct00039871) 18-65 years; * nonresponder to peg-intron plus rebetol in study p02370 exclusion criteria: * participants who did not participate in the p02370 study. * any medical condition, including but not limited to decompensated liver disease, malignancy or substance abuse, that developed during the p02370 study which could interfere with the participant's participation in and completion of this study.
investigational performance evaluation of the nanomix elab® covid-19 rapid antigen panel with samples from covid-19 positive and negative human subjects

Conditions: Covid19

Summary: prospective samples will be collected to evaluate the agreement between a eua rt-pcr test as the comparator method against the nanomix elab® system.


Eligibility criteria:
inclusion criteria: * 18 years of age or older * male or female * willing and able to provide informed consent * symptomatic or asymptomatic * the eua rt-pcr sample must be collected within one (1) day of the sample collected for testing by the nanomix elab® covid-19 rapid antigen panel. exclusion criteria: * subjects without both a valid eua rt-pcr test result and a valid nanomix elab® covid-19 rapid antigen results will be excluded * subjects not being able to provide consent